CA2431068A1 - Crystalline forms of atorvastatin - Google Patents

Crystalline forms of atorvastatin Download PDF

Info

Publication number
CA2431068A1
CA2431068A1 CA002431068A CA2431068A CA2431068A1 CA 2431068 A1 CA2431068 A1 CA 2431068A1 CA 002431068 A CA002431068 A CA 002431068A CA 2431068 A CA2431068 A CA 2431068A CA 2431068 A1 CA2431068 A1 CA 2431068A1
Authority
CA
Canada
Prior art keywords
crystalline forms
atorvastatin
directed
present
forms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002431068A
Other languages
French (fr)
Other versions
CA2431068C (en
Inventor
Paul Adriaan Van Der Schaaf
Fritz Blatter
Martin Szelagiewicz
Kai-Uwe Schoening
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Ciba Specialty Chemicals Holding Inc.
Paul Adriaan Van Der Schaaf
Fritz Blatter
Martin Szelagiewicz
Kai-Uwe Schoening
Teva Pharmaceutical Industries Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Specialty Chemicals Holding Inc., Paul Adriaan Van Der Schaaf, Fritz Blatter, Martin Szelagiewicz, Kai-Uwe Schoening, Teva Pharmaceutical Industries Ltd. filed Critical Ciba Specialty Chemicals Holding Inc.
Priority to CA002622697A priority Critical patent/CA2622697A1/en
Priority to CA002623599A priority patent/CA2623599A1/en
Priority to CA002622477A priority patent/CA2622477A1/en
Priority to CA002626317A priority patent/CA2626317A1/en
Priority to CA002622727A priority patent/CA2622727A1/en
Priority to CA002623600A priority patent/CA2623600A1/en
Publication of CA2431068A1 publication Critical patent/CA2431068A1/en
Application granted granted Critical
Publication of CA2431068C publication Critical patent/CA2431068C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The present invention is directed to new crystalline forms of Atorvastatin calcium (2:1), referred to hereinafter as polymorphic Forms X, A, B, B2, C, D
and E. Furthermore, the present invention is directed to processes for the preparation of these crystalline forms and pharmaceutical compositions comprising the crystalline forms.
CA002431068A 2000-12-27 2001-12-19 Crystalline forms of atorvastatin Expired - Fee Related CA2431068C (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CA002622697A CA2622697A1 (en) 2000-12-27 2001-12-19 Crystalline forms of atorvastatin
CA002623599A CA2623599A1 (en) 2000-12-27 2001-12-19 Crystalline forms of atorvastatin
CA002622477A CA2622477A1 (en) 2000-12-27 2001-12-19 Crystalline forms of atorvastatin
CA002626317A CA2626317A1 (en) 2000-12-27 2001-12-19 Crystalline forms of atorvastatin
CA002622727A CA2622727A1 (en) 2000-12-27 2001-12-19 Crystalline forms of atorvastatin
CA002623600A CA2623600A1 (en) 2000-12-27 2001-12-19 Crystalline forms of atorvastatin

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00811249 2000-12-27
EP00811249.2 2000-12-27
PCT/EP2001/015012 WO2002051804A1 (en) 2000-12-27 2001-12-19 Crystalline forms of atorvastatin

Related Child Applications (6)

Application Number Title Priority Date Filing Date
CA002626317A Division CA2626317A1 (en) 2000-12-27 2001-12-19 Crystalline forms of atorvastatin
CA002622477A Division CA2622477A1 (en) 2000-12-27 2001-12-19 Crystalline forms of atorvastatin
CA002622697A Division CA2622697A1 (en) 2000-12-27 2001-12-19 Crystalline forms of atorvastatin
CA002623599A Division CA2623599A1 (en) 2000-12-27 2001-12-19 Crystalline forms of atorvastatin
CA002623600A Division CA2623600A1 (en) 2000-12-27 2001-12-19 Crystalline forms of atorvastatin
CA002622727A Division CA2622727A1 (en) 2000-12-27 2001-12-19 Crystalline forms of atorvastatin

Publications (2)

Publication Number Publication Date
CA2431068A1 true CA2431068A1 (en) 2002-07-04
CA2431068C CA2431068C (en) 2008-06-10

Family

ID=8175112

Family Applications (7)

Application Number Title Priority Date Filing Date
CA002622477A Abandoned CA2622477A1 (en) 2000-12-27 2001-12-19 Crystalline forms of atorvastatin
CA002626317A Abandoned CA2626317A1 (en) 2000-12-27 2001-12-19 Crystalline forms of atorvastatin
CA002623599A Abandoned CA2623599A1 (en) 2000-12-27 2001-12-19 Crystalline forms of atorvastatin
CA002622697A Abandoned CA2622697A1 (en) 2000-12-27 2001-12-19 Crystalline forms of atorvastatin
CA002623600A Abandoned CA2623600A1 (en) 2000-12-27 2001-12-19 Crystalline forms of atorvastatin
CA002622727A Abandoned CA2622727A1 (en) 2000-12-27 2001-12-19 Crystalline forms of atorvastatin
CA002431068A Expired - Fee Related CA2431068C (en) 2000-12-27 2001-12-19 Crystalline forms of atorvastatin

Family Applications Before (6)

Application Number Title Priority Date Filing Date
CA002622477A Abandoned CA2622477A1 (en) 2000-12-27 2001-12-19 Crystalline forms of atorvastatin
CA002626317A Abandoned CA2626317A1 (en) 2000-12-27 2001-12-19 Crystalline forms of atorvastatin
CA002623599A Abandoned CA2623599A1 (en) 2000-12-27 2001-12-19 Crystalline forms of atorvastatin
CA002622697A Abandoned CA2622697A1 (en) 2000-12-27 2001-12-19 Crystalline forms of atorvastatin
CA002623600A Abandoned CA2623600A1 (en) 2000-12-27 2001-12-19 Crystalline forms of atorvastatin
CA002622727A Abandoned CA2622727A1 (en) 2000-12-27 2001-12-19 Crystalline forms of atorvastatin

Country Status (23)

Country Link
US (4) US7538136B2 (en)
EP (2) EP1345896B1 (en)
JP (2) JP2004516311A (en)
KR (1) KR100790766B1 (en)
CN (1) CN1273449C (en)
AT (1) ATE420070T1 (en)
AU (1) AU2002224952B2 (en)
CA (7) CA2622477A1 (en)
CZ (1) CZ20032019A3 (en)
DE (1) DE60137364D1 (en)
ES (1) ES2319870T3 (en)
HR (1) HRP20030607A2 (en)
HU (1) HUP0302519A3 (en)
IL (1) IL156280A0 (en)
IS (1) IS6859A (en)
MX (1) MXPA03005879A (en)
NO (1) NO20032758D0 (en)
NZ (1) NZ527048A (en)
PL (1) PL365312A1 (en)
PT (1) PT1345896E (en)
SK (1) SK9532003A3 (en)
WO (1) WO2002051804A1 (en)
ZA (1) ZA200304297B (en)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7411075B1 (en) 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
PL362472A1 (en) * 2000-11-03 2004-11-02 Teva Pharma Atorvastatin hemi-calcium form vii
US7501450B2 (en) 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
CA2622477A1 (en) * 2000-12-27 2002-07-04 Teva Pharmaceutical Industries Ltd. Crystalline forms of atorvastatin
EP1423364B1 (en) * 2001-06-29 2015-11-04 Warner-Lambert Company LLC Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin)
US7074818B2 (en) 2001-07-30 2006-07-11 Dr. Reddy's Laboratories Limited Crystalline forms VI and VII of Atorvastatin calcium
EE200400048A (en) * 2001-07-30 2004-04-15 Dr. Reddy's Laboratories Ltd. Crystalline Forms VI and VII of Atorvastatin Calcium
EP1425287A4 (en) * 2001-08-16 2005-09-07 Teva Pharma Processes for preparing calcium salt forms of statins
EP1572638A4 (en) * 2001-08-31 2010-05-05 Morepen Lab Ltd An improved process for the preparation of amorphous atorvastatin calcium salt (2:1)
UA77990C2 (en) * 2001-12-12 2007-02-15 Crystalline calcium salt of (2:1) [r-(r*,r*)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrroleheptanic acid
CN100406436C (en) * 2002-02-15 2008-07-30 特瓦制药工业有限公司 Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation, as well as novel processes for preparing atorvastatin hemi-calcium forms I, VIII and IX
WO2003070665A2 (en) 2002-02-19 2003-08-28 Teva Pharmaceutical Industries Ltd. Desolvating solvates of atorvastatin hemi-calcium
WO2004022053A1 (en) * 2002-09-03 2004-03-18 Morepen Laboratories Limited Atorvastatin calcium form vi or hydrates thereof
AU2003297594A1 (en) * 2002-11-28 2004-06-23 Teva Pharmaceutical Industries Ltd. Crystalline form f of atorvastatin hemi-calcium salt
EP1424324A1 (en) * 2002-11-28 2004-06-02 Teva Pharmaceutical Industries Limited Crystalline form F of Atorvastatin hemi-calcium salt
US7655692B2 (en) 2003-06-12 2010-02-02 Pfizer Inc. Process for forming amorphous atorvastatin
US20050271717A1 (en) 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
EP1761489A1 (en) * 2004-03-17 2007-03-14 Ranbaxy Laboratories Limited Crystalline form of atorvastatin hemi calcium
WO2005092852A1 (en) 2004-03-17 2005-10-06 Ranbaxy Laboratories Limited Process for the production of atorvastatin calcium in amorphous form
ES2739493T3 (en) 2004-05-05 2020-01-31 Pfizer Prod Inc Salt forms of atorvastatin with benetamine
EP1767625A4 (en) 2004-06-11 2007-12-05 Ginkgo Biomedical Res Inst Co Activity regulator for interferon producing cell
WO2006008091A2 (en) * 2004-07-16 2006-01-26 Lek Pharmaceuticals D.D. Oxidative degradation products of atorvastatin calcium
CA2754932C (en) 2004-07-20 2014-04-01 Warner-Lambert Company Llc Novel forms of [r-(r*,r*)]-2-(4-fluorophenyl)-.beta.,.delta.-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1)
NZ554541A (en) 2004-10-28 2011-01-28 Warner Lambert Co Process for forming amorphous atorvastatin
WO2006048894A1 (en) * 2004-11-05 2006-05-11 Morepen Laboratories Limited Novel crystalline forms of atorvastatin calcium and processes for preparing them.
CA2499047A1 (en) * 2005-03-01 2006-09-01 Apotex Pharmachem Inc. Process for producing atorvastatin hemicalcium
EP1868993B1 (en) * 2005-04-08 2014-04-30 EGIS Gyógyszergyár Nyilvánosan Müködõ Részvénytársaság Process for the preparation of a new crystalline atorvastatin hemicalcium salt polymorph form
CA2547216A1 (en) 2005-09-21 2007-03-21 Renuka D. Reddy Process for annealing amorphous atorvastatin
ATE466840T1 (en) 2005-11-21 2010-05-15 Warner Lambert Co NEW FORMS OF ÄR-(R*,R*)Ü-2-(4-FLUORPHENYL)-B,D-DIHYDROXY-5-(-METHYLETHYL)-3-PHENYL-4-Ä(PHENYLAMINO)CARBONYLÜ-1H-PYRROLE -1-HEPTANIC ACID MAGNESIUM
CA2633268A1 (en) 2005-12-13 2007-06-21 Teva Pharmaceutical Industries Ltd. Crystal form of atorvastatin hemi-calcium and processes for preparation thereof
EP1810667A1 (en) 2006-01-20 2007-07-25 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising amorphous atorvastatin
CA2655881A1 (en) * 2006-06-28 2008-01-03 Teva Pharmaceutical Industries Ltd. Crystalline forms of atorvastatin
WO2009007856A2 (en) * 2007-07-11 2009-01-15 Actavis Group Ptc Ehf Novel polymorph of atorvastatin calcium and use thereof for the preparation of amorphous atorvastatin calcium
KR20120011249A (en) * 2010-07-28 2012-02-07 주식회사 경보제약 Novel Crystal Form of Atorvastatin Hemi-Calcium, Hydrate thereof, and Method of Producing the Same
CN104983702A (en) * 2015-07-23 2015-10-21 青岛蓝盛洋医药生物科技有限责任公司 Atorvastatin calcium composition tablet for treating hypercholesterolemia
JP2019167295A (en) * 2016-07-04 2019-10-03 ゼリア新薬工業株式会社 Method for producing calcium salt of 1, 5-benzodiazepine compound

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI94339C (en) 1989-07-21 1995-08-25 Warner Lambert Co Process for the preparation of pharmaceutically acceptable [R- (R *, R *)] - 2- (4-fluorophenyl) -, - dihydroxy-5- (1-methylethyl) -3-phenyl-4 - [(phenylamino) carbonyl] -1H- for the preparation of pyrrole-1-heptanoic acid and its pharmaceutically acceptable salts
SG45369A1 (en) * 1993-01-19 1998-10-16 Warner Lambert Co Stable oral ci-981 formulation and process of preparing same
US5298627A (en) 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
HRP960312B1 (en) 1995-07-17 2001-10-31 Warner Lambert Co NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1)
HRP960313B1 (en) * 1995-07-17 2002-08-31 Warner Lambert Co Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
JP3296564B2 (en) * 1995-07-17 2002-07-02 ワーナー−ランバート・コンパニー Crystalline [R- (R ▲ *, R ▲ *)]-2- (4-fluorophenyl) -β, δ-dihydroxy-5- (1-methylethyl) -3-phenyl-4 -[(Phenylamino) carbonyl] -1H-pyrrole-1-heptanoic acid hemicalcium salt (atorvastatin)
WO2001036384A1 (en) * 1999-11-17 2001-05-25 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
US7411075B1 (en) * 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
DE60026737T2 (en) * 1999-12-17 2006-09-21 Pfizer Science And Technology Ireland Ltd., Dun Laoghaire PROCESS FOR PREPARING CRYSTALLINE ATORVASTINE KALCIUM
PL362472A1 (en) * 2000-11-03 2004-11-02 Teva Pharma Atorvastatin hemi-calcium form vii
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
CA2622477A1 (en) * 2000-12-27 2002-07-04 Teva Pharmaceutical Industries Ltd. Crystalline forms of atorvastatin
WO2002057228A1 (en) 2001-01-17 2002-07-25 Biocon India Limited Atorvastatin calcium
WO2002057229A1 (en) * 2001-01-19 2002-07-25 Biocon India Limited FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN)
SI20814A (en) 2001-01-23 2002-08-31 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Preparation of amorphous atorvastatin
SI20848A (en) 2001-03-14 2002-10-31 Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. Pharmaceutical formulation containing atorvastatin calcium
EP1423364B1 (en) * 2001-06-29 2015-11-04 Warner-Lambert Company LLC Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin)
EE200400048A (en) * 2001-07-30 2004-04-15 Dr. Reddy's Laboratories Ltd. Crystalline Forms VI and VII of Atorvastatin Calcium

Also Published As

Publication number Publication date
HRP20030607A2 (en) 2005-06-30
CN1483022A (en) 2004-03-17
NZ527048A (en) 2004-12-24
CA2431068C (en) 2008-06-10
CA2626317A1 (en) 2002-07-04
EP1345896B1 (en) 2009-01-07
US20090281162A1 (en) 2009-11-12
CA2622477A1 (en) 2002-07-04
US20040220255A1 (en) 2004-11-04
CA2622727A1 (en) 2002-07-04
ES2319870T3 (en) 2009-05-14
KR100790766B1 (en) 2008-01-03
CA2623600A1 (en) 2002-07-04
JP2004516311A (en) 2004-06-03
MXPA03005879A (en) 2003-09-10
SK9532003A3 (en) 2004-04-06
AU2002224952B2 (en) 2007-04-05
CZ20032019A3 (en) 2003-10-15
WO2002051804A1 (en) 2002-07-04
JP2009221216A (en) 2009-10-01
IL156280A0 (en) 2004-01-04
DE60137364D1 (en) 2009-02-26
NO20032758L (en) 2003-06-17
HUP0302519A3 (en) 2008-10-28
PT1345896E (en) 2009-02-19
CA2623599A1 (en) 2002-07-04
EP2000461A1 (en) 2008-12-10
PL365312A1 (en) 2004-12-27
NO20032758D0 (en) 2003-06-17
IS6859A (en) 2003-06-24
ZA200304297B (en) 2004-08-16
US7538136B2 (en) 2009-05-26
KR20030064880A (en) 2003-08-02
ATE420070T1 (en) 2009-01-15
US20060205805A1 (en) 2006-09-14
HUP0302519A2 (en) 2003-12-29
EP1345896A1 (en) 2003-09-24
CA2622697A1 (en) 2002-07-04
CN1273449C (en) 2006-09-06
US20030114686A1 (en) 2003-06-19

Similar Documents

Publication Publication Date Title
CA2431068A1 (en) Crystalline forms of atorvastatin
CA2392096A1 (en) Polymorphic form of atorvastatin calcium
CA2378148A1 (en) Nematicidal trifluorobutenes
CA2429590A1 (en) Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
WO2003006425A3 (en) Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
CA2463947A1 (en) Montelukast granule formulation
WO2003013512A3 (en) Crystalline forms of fluvastatin sodium
CA2419314A1 (en) Preparation of risperidone
CA2450093A1 (en) Stable polymorph of flibanserin, technical process for its preparation and the use thereof for preparing medicaments
AU2001284385A1 (en) An improved process for the preparation of amorphous atorvastatin calcium salt (2:1)
TNSN04024A1 (en) Novel crystalline polymorphic forms of lercanidipine hydrochloride and process for their preparation
CA2508871A1 (en) Crystalline form f of atorvastatin hemi-calcium salt
ID28601A (en) PREPARATION PROCESS FOR COMPOUNDS OF 1,4-DIHYDROPIRIDINE COMPOUNDS
CA2455298A1 (en) Condensed polycyclic compounds
WO2004048381A3 (en) Pyrazoloazepine compounds as pharmaceutical agents
WO2003007872A3 (en) Process for the preparation of citalopram hydrobromide
CA2355720A1 (en) New substituted 3-phenoxy and 3-phenylalkyloxy-2-phenyl-propylamines
WO2003005970A3 (en) Carvedilol polymorph
WO2004034983A3 (en) Preparation of triazospiro compounds
CA2338649A1 (en) New phenylethylamine derivatives, processes for preparing them and their use as pharmaceutical compositions
CA2385871A1 (en) Ltb4 antagonist, processes for the preparation thereof and its use as a pharmaceutical composition
CA2535742A1 (en) Preparation of risperidone
AU2001277727A1 (en) Benzoylaminoisoindoline compounds, processes for the preparation of the same andintermediates for the synthesis thereof
WO2002020490A3 (en) Process to produce halo-4-phenoxyquinolines
AU2001237791A1 (en) Process for the preparation of (r)-2-bromo-3-phenyl-propionic acid

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed